TS03 Inc Trust Units TSTIF

From Canaccord's Morning Coffee tomorrow: "Short Squeeze?"

[echo2]

"TSO3* (TOS : TSX : $2.95), Net Change: 0.00, % Change: 0.00%, Volume: 1,328,813

IT’S BEEN A LONG TIME COMING BUT AN INFLECTION POINT MAY FINALLY BE HERE. On Monday, TSO3 announced that the U.S. Food and Drug Administration (FDA) had cleared its expanded indications for use of its Sterizone VP4 Sterilizer. By allowing broad claims on the end-sterilization of multiple-channel flexible endoscopes, Canaccord Genuity Life Sciences Analyst Neil Maruoka believes that the FDA has changed the dynamics of the market as no other competing sterilizer is capable of addressing this need. With over 4 million endoscopic procedures performed annually in the U.S., VP4 has been approved to sterilize the majority of these devices (with the exception of duodenoscopes, which represent approximately 500K procedures); this should give a good idea of the magnitude of the opportunity ahead for TSO3. Maruoka expects that TSO3 could eventually enjoy a dominant position in the market, as adoption of VP4 will allow customers to "futureproof" against regulatory changes. Nonetheless, Maruoka does not believe that the effects are going to be evident overnight, and it will likely take some time for the market to adapt. With a disruptive technology that has the potential to dominate its market, Maruoka believes that the FDA’s implicit approval could pique interest from other players. As the installed base for VP4 continues to grow, Maruoka believes that TSO3 could be an attractive target for either its partner or other parties interested in accessing a mature market with high barriers to entry. Short squeeze? There are currently ~3.82 million shares short on TSO3. The company has ~91 million shares outstanding."


Certainly, no financing needed here, at all!!